This site is intended for U.S. Healthcare professionals

For patients with Parkinson's Disease

Where will they

XADAGO NEXT?

XADAGO, an adjunct to levodopa, improves on time–without troublesome dyskinesia1

learn more

The limitations

of Levodopa2,3

Extending symptom control,

expanding the possibilities

Find out more

Xadago efficacy1

Improvements in on time without troublesome dyskinesia, off time, and motor function

View the data

Who can Xadago help?

Identifying the right patients for once-daily Xadago

Click here
References
  1. XADAGO® (safinamide) [Prescribing Information]. Louisville, KY: US WorldMeds, LLC; 2017.
  2. Hickey P, Stacy M. Available and emerging treatments for Parkinson’s disease: a review. Drug Des Devel Ther. 2011:241-254.
  3. Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord.2005;20(11):S11-S16.